Evidence map›Paper›PMID 42316368›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2026

Effect of Body Mass Index on the Efficacy and Safety of Esaxerenone Versus Trichlormethiazide for the Treatment of Japanese Patients with Uncontrolled Essential Hypertension: A Subanalysis of the Excite-HT Study.

Tomohiro Katsuya, Kazuomi Kario, Mitsuru Ohishi, Tatsuo Shimosawa, Kazuhito Shiosakai, Taketoshi Furugori, Takashi Taguchi, EXCITE‐HT investigators

Abstract readRandomized Controlled TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tomohiro KatsuyaKatsuya Clinic, Amagasaki, Hyogo, Japan.ORCID https://orcid.org/0000-0002-8892-8828
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Mitsuru OhishiDepartment of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima, Japan.
Tatsuo ShimosawaDepartment of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
Kazuhito ShiosakaiData Intelligence Department, Daiichi Sankyo Co., Ltd, Shinagawa-ku, Tokyo, Japan.
Taketoshi FurugoriPrimary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, Japan.
Takashi TaguchiPrimary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd, Chuo-ku, Tokyo, Japan.
EXCITE‐HT investigators

Funding

Daiichi Sankyo Co., Ltd.
6 · The paper itself

Abstract

This prespecified, exploratory, body mass index (BMI)-stratified analysis of the randomized, open-label EXCITE-HT study examined whether esaxerenone elicits a blood pressure (BP)-lowering effect similar to trichlormethiazide in Japanese patients with uncontrolled essential hypertension. Patients received either esaxerenone or trichlormethiazide for 12 weeks and were grouped by baseline BMI: <25 kg/m

Indexed as

Antihypertensive AgentsBody Mass IndexHypertensionTrichlormethiazideAgedBlood PressureDiureticsEast Asian PeopleEssential HypertensionFemaleHumansJapanMaleMiddle AgedPyrrolesSulfonesAntihypertensive AgentsDiureticsesaxerenonePyrrolesSulfonesTrichlormethiazide

Identifiers

PMID42316368
PMCPMC13279341

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.